SIGA Technologies

US: SIGA

Market Cap$485.3m

Last Close $6.38

SIGA Technologies is a commercial-stage health security company focused on the treatment of smallpox and other orthopoxviruses. It has contracts with both the US and Canadian governments for TPOXX, its treatment for smallpox.

More SIGA Technologies content >

Investment summary

SIGA Technologies is a commercial-stage company focusing on health security. Its lead program is oral TPOXX (tecovirimat), which was approved by the FDA in 2018 for the treatment of smallpox and is active against all orthopoxviruses. Importantly, in 2018 SIGA was awarded a 60-month contract (with options to extend to 2028) of up to $602m from the US Biomedical Advanced Research and Development Authority (BARDA). The bulk of the BARDA contract is related to the oral version of TPOXX in people with smallpox. The company is looking to expand its franchise with an IV version (NDA was submitted in May), a liquid formulation mainly for use in small children and a label expansion for TPOXX for use in post-exposure prophylaxis.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2019A 26.7 0.0 (15.3) (15.22) N/A N/A
2020A 125.0 84.5 82.0 81.82 7.8 7.1
2021E 119.2 75.1 75.2 74.65 8.5 8.8
2022E 124.5 78.9 79.4 79.34 8.0 7.8
Industry outlook

Smallpox is a very serious life-threatening disease caused by the variola virus. The literature suggests a death rate of up to 30% (compared to around 2% for COVID-19). According to CDC forecasts, over 50 million people could be infected in a smallpox outbreak.

Last updated on 21/06/2021
Content on SIGA Technologies
SIGA Technologies – executive interview
Healthcare | Edison TV | 9 March 2021
View more
Register to receive research on SIGA Technologies as it is published
Share price graph
Balance sheet
Forecast net cash (US$m) 166.3
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (8.1) (6.5) 8.0
Relative* (9.6) (13.4) (20.8)
52-week high/low US$7.8/US$5.6
*% relative to local index
Key management
Eric Rose Chairman
Daniel Luckshire Executive VP and CFO